Article

Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular risk

2026-03-09

Abstract excerpt

<h4>Background and Aims</h4> Angiotensinogen synthesis inhibitors have shown promising blood pressure-lowering effects in early-stage trials, but their impact on cardiovascular outcomes remains unknown. We investigated associations between genetic variants mimicking angiotensinogen synthesis inhibition and cardiovascular phenotypes. <h4>Methods</h4> We developed a genetic proxy for hepatic angiotensinogen synthe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0f9126f1-9cba-5916-a33b-6cd3eae20123
DOI: 10.64898/2026.03.08.26347887

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular riskDOI 10.64898/2026.03.08.26347887Read

Assessing the efficacy and safety of angiotensinogen inhibition using human geneticsSemantic proximity Read

ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization studySemantic proximity Read

Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and ColocalisationSemantic proximity Read

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.Semantic proximity Read

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancersSemantic proximity Read

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read

Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study.Semantic proximity Read

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.Semantic proximity Read

Beyond the 2025 guidelines: tailoring hypertension management to the underlying pathogenic pathway in the age of precision medicine.Semantic proximity Read

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity Read

Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.Semantic proximity Read